Trial | NCT03560804  Report issue

Title

Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic.

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    60
The principal aim of the study is to determine whether the hemodynamic parameters measured with the two methods -impedance cardiography and applanation tonometry- can be predictive of the antihypertensive effect of two different classes of drugs, ATII antagonists and diuretics.

The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months.

The other basic aim of the study is to determine whether there is a difference (>6mmHg) between the two drugs regarding the reduction of the mean 24hour blood pressure and the effect of them on the hemodynamic parameters.

The hemodynamic parameters that will be measured by applanation tonometry are augmentation index, central blood pressure and pulse wave velocity.

The hemodynamic parameters that will be measured by impedance cardiography are cardiac index, thoracic fluid content index, systemic vascular resistance index and others.
The principal aim of the study is to determine whether the hemodynamic parameters measured with the two methods -impedance cardiography and applanation tonometry- can be predictive of the antihypertensive effect of two different classes of drugs, ATII antagonists and diuretics.

The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months.
Study Started
Nov 10
2014
Primary Completion
Sep 15
2017
Study Completion
Sep 15
2017
Last Update
Jun 18
2018

Drug Olmesartan

Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.

  • Other names: Olartan

Drug Chlorthalidone

Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.

  • Other names: Hygroton

Olmesartan Active Comparator

ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target

Chlorthalidone Active Comparator

Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target

Criteria 

Inclusion Criteria:

Age > 18 years
Drug naive patients with 1st or 2nd grade Arterial Hypertension according to the ESH/ESC guidelines 2013
The patient has signed the concent form

Exclusion Criteria:

Secondary Hypertension
3rd grade of Arterial Hypertension
Chronic renal failure
Diabetes Mellitus
Sleep apnea syndrome
Chronic or acute inflammatory diseases
Stroke, myocardial infarction, angina pectoris in the past 6 months
Heart failure
Liver disease
Neoplasms
Pregnancy
Valvular Heart disease
Heigt < 120cm or > 230cm, Weight <30kg or >155kg
Heart Arrhytmias
Artificial cardiac pacemaker
Hemodymanic unstable patients
No Results Posted